Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study

BACKGROUND: Anemia has been a known prognostic factor in metastatic hormone-sensitive prostate cancer (mHSPC). We therefore examined the effect of anemia on the efficacy of upfront abiraterone acetate (ABI) in patients with mHSPC. METHODS: We retrospectively evaluated 66 mHSPC patients with high tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Okamoto, Teppei, Noro, Daisuke, Hatakeyama, Shingo, Narita, Shintaro, Mitsuzuka, Koji, Sakurai, Toshihiko, Kawamura, Sadafumi, Hoshi, Senji, Shimoda, Jiro, Tanaka, Toshikazu, Kawaguchi, Toshiaki, Ishidoya, Shigeto, Ito, Akihiro, Tsuchiya, Norihiko, Habuchi, Tomonori, Ohyama, Chikara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152305/
https://www.ncbi.nlm.nih.gov/pubmed/34034691
http://dx.doi.org/10.1186/s12885-021-08206-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152305/
https://www.ncbi.nlm.nih.gov/pubmed/34034691
http://dx.doi.org/10.1186/s12885-021-08206-8

Ejemplares similares